Medicilon entered Zhangjiang Runhe International Office Garden as the first batch of contracted enterprises

Zhangjiang Runhe International Office Garden Opened

On April 15, 2020, the opening ceremony of Zhangjiang Runhe International Office Garden was successfully held.  The Member of the Standing Committee and Deputy Mayor of Shanghai Municipal Committee, Qing Wu, led several of the Shanghai government officials and business representatives attended the ceremony.

Zhangjiang Runhe International Office Garden has a planned area of 1 million square meters (10.7 million sq. ft.), a buildable construction area of 1.599 million square meters (17 million sq.ft.), a planned industrial population of approximately 45,200 people and a mixed land use for industrial research and development, which can fulfill the needs of pharmaceutical industry trial production and market licensing.

Medicilon is the first batch to settled in the Garden

Medicilon entered Zhangjiang Runhe International Office Garden as the first batch of contracted enterprises. Dr. Chen Chunlin, founder and CEO of Medicilon, participated in the signing ceremony.

Medicilon is the first enterprise listed on the Sci-Tech Innovation Board to settle in the Zhangjiang Runhe International Office Garden. As a biopharmaceutical CRO, Medicilon will use a comprehensive and integrated preclinical research service platform to assist in the research and development of new drugs.

Medicilon boosts preclinical drug development

Since the founding in Zhangjiang in 2004, Medicilon has developed steadily and in proficient in innovation.  Under the leadership of Zhangjiang Science City, Medicilon has developed into a professional preclinical R&D CRO, covering the entire process of pharmaceutical preclinical new drug research such as drug discovery, pharmaceutical research and preclinical research. Medicilon has nearly 600 active collaborative partners worldwide and helped the global pharmaceutical companies and scientific research institutions on their drug development and IND filing declaration.  Medicilon has successfully completed nearly 100 R&D projects to pass the NMPA or FDA registration.